2022 April
-1
archive,date,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

April 2022

n patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive induction therapy, Ivosidenib/Azacitidine combination showed significantly longer EFS compared to Azacitidine at a median follow-up of 12.4 months. The median OS was 24.0 months with Ivosidenib/Azacitidine and 7.9 months with Azacitidine. Febrile neutropenia and infections were less frequent with Ivosidenib/Azacitidine than Azacitidine.
(Ref: Montesinos P et al. N Engl J Med. April 21,2022)

#oncologyresearch #drugdevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6926072382784704512

In patients with platinum-sensitive, recurrent ovarian cancer previously treated with at least two platinum-based regimens, Fuzuloparib as a maintenance therapy showed a significantly improved progression-free survival compared with placebo, regardless of germline BRCA 1/2 mutation. (Ref: Li N et al. J Clin Oncol. April 11, 2022)
#oncologyresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6923581090574000128

Indolent MCL patients treated with frontline ibrutinib plus rituximab showed an overall response of 84% after 12 cycles of treatment, with 80% of patients experiencing a CR. Undetectable MRD in the peripheral blood was achieved in 87% of patients. The estimated PFS at 36 months was 93%. At 2 years, 69% of patients could discontinue ibrutinib because of undetectable MRD. (Ref: Giné E et al. J Clin Oncol. 2022)
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6921011455219646464

In patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower with trastuzumab deruxtecan than trastuzumab emtansine [Hazard ratio – 0.28 (p<0.001)]. The corresponding overall survival rate was 94.1% and 85.9% after 12 months, and the overall response was 79.7% and 34.2%. (Ref: Cortés J, et al. N Engl J Med March 24, 2022).
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6915618089447387136